| Pack Size | Qty | Lead Time | Price | Quantity |
Lot Number
CAS #
*This document is like a lab demo—an example Certificate of Analysis (COA) that showcases what a COA looks like but may not match the latest batch in all its glory. Think of it as a chemistry experiment: close, but not quite the final reaction!
Share
Total BLR Stock
:
Bulk Quote| IUPAC name | 6-amino-5-fluoro-1H-pyrimidin-2-one |
| inchi | InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9) |
| inchi key | XRECTZIEBJDKEO-UHFFFAOYSA-N |
| molecular formula | C4H4FN3O |
| synonyms | |
| Compound Description |
| Molecular Weight: | 129.09 g/mol |
| XLogP3: | -0.9 |
| Hydrogen Bond Donor Count: | 2 |
| Hydrogen Bond Acceptor Count: | 3 |
| Rotatable Bond Count: | 0 |
| Exact Mass: | 129.03383992 g/mol |
| Monoisotopic Mass: | 129.03383992 g/mol |
| Topological Polar Surface Area: | 67.5 Ų |
| Heavy Atom Count: | 9 |
| Formal Charge: | 0 |
| Complexity: | 208 |
| Isotope Atom Count: | 0 |
| Defined Atom Stereocenter Count: | 0 |
| Undefined Atom Stereocenter Count: | 0 |
| Defined Bond Stereocenter Count: | 0 |
| Undefined Bond Stereocenter Count: | 0 |
| Covalently-Bonded Unit Count: | 1 |
| Compound Is Canonicalized: | Yes |
| hazard signal | Warning |
| hazard classes and categories | |
| precautionary statement codes | P203, P280, P318, P405, and P501 |
| hazard statements |
| toxicity summary | IDENTIFICATION AND USE: Flucytosine is a solid. It is used as antifungal agent and antimetabolite. Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus. HUMAN STUDIES: It is reasonable to expect that overdosage may produce pronounced manifestations of the known clinical adverse reactions. Prolonged serum concentrations in excess of 100 ug/mL may be associated with an increased incidence of toxicity, especially gastrointestinal , hematologic and hepatic . A case of urinary crystalluria was reported in a patient during treatment with flucytosine. Flucytosine-associated diarrhea has been described in 6%-10% of patients receiving the drug. A potentially fatal ulcerating enterocolitis has been reported in 4 patients. ANIMAL STUDIES: In mice, 400 mg/kg/day of flucytosine administered on days 7 to 13 of gestation was associated with a low incidence of cleft palate that was not statistically significant. Flucytosine was not teratogenic in rabbits up to a dose of 100 mg/kg/day administered on days 6 to 18 of gestation. Flucytosine was shown to be teratogenic in the rat at doses of 40 mg/kg/day administered on days 7 to 13 of gestation. At higher doses administered on days 9 to 12 of gestation), cleft lip and palate and micrognathia were reported. The in utero treatment had no adverse effect on the fertility or reproductive performance of the offspring in mice. The mutagenic potential of flucytosine was evaluated in Ames-type studies with five different mutants of Salmonella typhimurium and no mutagenicity was detected in the presence or absence of activating enzymes. Flucytosine was nonmutagenic in three different repair assay systems.Although the exact mode of action is unknown, it has been proposed that flucytosine acts directly on fungal organisms by competitive inhibition of purine and pyrimidine uptake and indirectly by intracellular metabolism to 5-fluorouracil. Flucytosine enters the fungal cell via cytosine permease; thus, flucytosine is metabolized to 5-fluorouracil within fungal organisms. The 5-fluorouracil is extensively incorporated into fungal RNA and inhibits synthesis of both DNA and RNA. The result is unbalanced growth and death of the fungal organism. It also appears to be an inhibitor of fungal thymidylate synthase. |
| symptoms | |
| carcinogen classification | default_key: No indication of carcinogenicity to humans . |
